Q-omics provides the consensus-scored NENFP2 profile across patient tissues and cancer cell-line models. NENFP2 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NENFP2 is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, NENFP2 RNA expression shows 9,856 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRC, and LSCC as cancer lineages where NENFP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NENFP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NENFP2 survival associations across molecular data types. NENFP2 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NENFP2 RNA expression–survival associations across cancer types. High NENFP2 expression shows unfavorable associations in UVM, READ, CESC, LUAD and BLCA, but favorable associations in LAML. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NENFP2 RNA expression.
This table summarizes NENFP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NENFP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NENFP2 shows lower tumor expression in BRCA and higher tumor expression in KIRC. The KIRC box plot shows higher NENFP2 RNA expression in tumor versus normal tissue (log2 FC = +0.038, t-test p = .003).
This table shows molecular features associated with NENFP2 in patient tissues and cancer cell lines. In patient samples, NENFP2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
